Due to the limited number of neuroendocrine tumor samples in our cohort, we were unable to conduct a comparative analysis of the effects of TP53/RB1 co‐alteration in neuroendocrine versus non‐neuroendocrine tumors. Here, RB1 is linked to neuroendocrine neoplasm.